Search Results for "androgens"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for androgens. Results 11 to 19 of 19 total matches.

Osilodrostat (Isturisa) for Cushing's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021  (Issue 1617)
, cortisol withdrawal, or accumulation of adrenal hormone precursors and androgens. Osilodrostat can cause ...
The FDA has approved osilodrostat (Isturisa – Recordati), a cortisol synthesis inhibitor, for oral treatment of adults with Cushing's disease when surgical resection of the pituitary adenoma is not an option or has not been curative. Osilodrostat is the first cortisol synthesis inhibitor to be approved in the US for this indication. Other oral steroidogenesis inhibitors such as ketoconazole and metyrapone have been used off-label for this indication for many years.
Med Lett Drugs Ther. 2021 Feb 8;63(1617):21-3 |  Show IntroductionHide Introduction

Comparison Chart: Some Drugs for HFrEF

   
The Medical Letter on Drugs and Therapeutics • May 26, 2025  (Issue 1729)
inhibitor, or ARB and in those with renal impairment. . Spironolactone has anti-androgenic activity ...
View the Comparison Chart: Some Drugs for HFrEF
Med Lett Drugs Ther. 2025 May 26;67(1729):e1-15   doi:10.58347/tml.2025.1729b |  Show IntroductionHide Introduction

Addendum: Aducanumab (Aduhelm) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021  (Issue 1629)
reactions, but severe reactions are uncommon.19 Estrogenic and anti-androgenic activities ...
In June 2021, the FDA approved the IV amyloid beta-directed monoclonal antibody aducanumab (Aduhelm) for treatment of Alzheimer’s disease. The approval did not restrict use of the drug to patients with mild cognitive impairment or mild dementia, which was the population enrolled in the clinical trials. Now, Biogen, with the permission of the FDA, has made an addition to the labeling of the drug that says: Treatment with Aduhelm should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical...
Med Lett Drugs Ther. 2021 Jul 26;63(1629):120 |  Show IntroductionHide Introduction

Drugs for Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024  (Issue 1697)
into active metabolites of estrogens and androgens. Prasterone can be used as an alternative to a vaginal ...
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent urinary tract infection. Vasomotor symptoms (VMS; hot flashes, night sweats) often disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8   doi:10.58347/tml.2024.1697a |  Show IntroductionHide Introduction

Sunscreens

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025  (Issue 1731)
, but severe reactions are uncommon.24 Estrogenic and anti-androgenic activity and neurotoxicity ...
Excessive exposure to ultraviolet (UV) radiation can cause erythema, photoaging, and skin cancer. Sunscreens are widely used to reduce these risks, but questions remain about their effectiveness and safety. In 2021, the FDA proposed a rule that would require additional safety studies for some sunscreen active ingredients and mandate better UVA protection in sunscreen products.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):97-102   doi:10.58347/tml.2025.1731a |  Show IntroductionHide Introduction

Comparison Table: Some Oral Antiseizure Medications (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
, and with increased androgen concentrations in men Rare: fatal hepatic failure, life-threatening pancreatitis ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40   doi:10.58347/tml.2024.1708b |  Show IntroductionHide Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • May 26, 2025  (Issue 1729)
treatment. Spironolactone has anti-androgenic activity; it can cause erectile dysfunction and painful ...
Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) and those with an LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Patients with an LVEF of 41-49% have heart failure with mildly reduced or mid-range ejection fraction.
Med Lett Drugs Ther. 2025 May 26;67(1729):81-8   doi:10.58347/tml.2025.1729a |  Show IntroductionHide Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2023  (Issue 1676)
/7 regimens. Choice of Progestin – Desogestrel, norgestimate, and drospirenone are less androgenic ...
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also effective in preventing pregnancy. When used alone, barrier and behavioral methods generally have higher failure rates than other methods (see Table 1). Selection of a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80   doi:10.58347/tml.2023.1676a |  Show IntroductionHide Introduction

Drugs for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
abnormalities, hirsutism and menstrual disturbances in women, and increased serum androgen concentrations in men ...
When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of use, spectrum of activity, adverse effects, interactions with other drugs, presence of comorbid conditions, suitability for elderly persons and those with childbearing potential, and cost. Treatment should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8   doi:10.58347/tml.2024.1708a |  Show IntroductionHide Introduction